Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has recruited the first patient for its Phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD).
The EMDMA-001 trial has been designed to assess the safety, efficacy and cost-effectiveness of MDMA-assisted therapy for PTSD.
It aims to generate vital data that will strengthen Emyria's position as a leader in providing psychedelic-assisted therapy within a comprehensive multidisciplinary clinical service.
The news comes soon after Emyria announced it was acquiring the Pax Centre, Australias leading multidisciplinary psychological trauma care service.
It brings a top-tier clinical service into the EMD fold, expanding its capabilities as it develops therapies to meet a burgeoning market.
A report from InsightAce Analytics expects the total addressable market for psychedelic assisted therapies to reach US$8.31 billion by 2028.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/emyria-recruits-first-patient-for-mdma-assisted-therapy-trial-113667941
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Gio News UK journalist was involved in the writing and production of this article.